Appl. No. 10/688,759 Amdt. Dated September 16, 2010 Reply to Office Action of July 16, 2010

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application.

Listing of Claims:

- 1. 11. (Cancelled).
- 12. (Previously presented) A method of reducing neuronal cell death in a mammal suffering from or susceptible to neurodegenerative disease, cerebral ischaemia, traumatic neuronal injury, paralysis, or spinal cord injury, comprising administering to the mammal an effective amount of a 3-substituted indolone that is a C-Raf inhibitor or a pharmaceutically acceptable salt-thereof sufficient to reduce neuronal cell death.
- (Cancelled).
- 14. (Previously presented) A method of reducing apoptotic neuronal cell death in a mammal, comprising administering to the mammal an effective amount of a C-Raf inhibitor, or a pharmaceutically acceptable salt thereof.
- 15. (Previously presented) The method of claim 14, wherein said C-Raf inhibitor comprises {5- iodo-3-[(3.5-dibromo-4-hydroxyphenyl) methylene]-2-indolinone}.
- (Cancelled).
- 17. (Previously presented) The method of Claims 12 or 14 wherein said C-Raf inhibitor comprises an oxindole derivative, or a pharmaceutically acceptable salt thereof.
- 18. (Previously presented) The method of Claims 12 or 14 wherein said C-Raf inhibitor comprises a benzamide derivative, or a pharmaceutically acceptable salt thereof.
- (Previously presented) The method of Claim 18 wherein said C-Raf inhibitor comprises
 N-[5-(3- dimethylaminobenzamide)-2-methylphenyl]-4-hydroxybenzamide.
- (Previously presented) The method of Claims 12 or 14 wherein said C-Raf inhibitor reduces neuronal cell death via B-Raf regulation.
- (Previously presented) The method of Claim 20, wherein said C-Raf inhibitor reduces neuronal cell death by activating B-Raf.

Appl. No. 10/688,759 Amdt. Dated September 16, 2010 Reply to Office Action of July 16, 2010

- (Previously presented) The method of Claim 21, wherein said C-Raf inhibitor or a
 pharmaceutically acceptable salt thereof comprises an oxindole derivative.
- 23. (Previously presented) The method of Claim 22, wherein said C-Raf inhibitor comprises {5- iodo-3-[(3,5-dibromo-4-hydroxyphenyl) methylene]-2-indolinone} or a pharmaceutically acceptable salt thereof.
- (Currently amended) The method of Claim 20, wherein said C-Raf inhibitor or a
 pharmaceutically acceptable salt, complex or prodrug thereof, comprises a benzamide derivative,
 or a pharmaceutically acceptable salt thereof.
- (Previously presented) The method of Claim 24, wherein said benzamide derivative comprises N-[5-(3- dimethylaminobenzamide)-2-methylphenyl]-4-hydroxybenzamide or a pharmaceutically acceptable salt thereof.
- (Currently amended) The method of Claim 21, wherein said C-Raf inhibitor or a
 pharmaceutically acceptable salt, complex or prodrug thereof, comprises a benzamide derivative,
 or a pharmaceutically acceptable salt thereof.
- (Previously presented) The method of Claim 26, wherein said benzamide derivative comprises N-[5-(3- dimethylaminobenzamide)-2-methylphenyl]-4-hydroxybenzamide or a pharmaceutically acceptable salt thereof.
- (Previously presented) A method of reducing neuronal cell death in a mammal, comprising administering an effective amount of a C-Raf inhibitor or a pharmaceutically acceptable salt thereof.
- (Previously presented) The method of Claim 28, wherein said C-Raf inhibitor comprises an oxindole derivative.
- 30. (Previously presented) The method of Claim 28, wherein said C-Raf inhibitor comprises a benzamide derivative
- 31. (Previously presented) The method of Claims 28, wherein said C-Raf inhibitor reduces neuronal cell death via B-Raf regulation.
- 32. (Previously presented) The method of Claim 31, wherein said C-Raf inhibitor reduces neuronal cell death by B-Raf activation.

Appl. No. 10/688,759 Amdt. Dated September 16, 2010 Reply to Office Action of July 16, 2010

- 33. (Previously presented) The method of Claims 29 or 31 or 32, wherein said C-Raf inhibitor comprises {5- iodo-3-[(3.5-dibromo-4-hydroxyphenyl) methylene]-2-indolinone}.
- 34. (Previously presented) The method of Claims 29 or 31 or 32, wherein said C-Raf inhibitor comprises N-[5-(3- dimethylaminobenzamide)-2-methylphenyl]-4-hydroxybenzamide.
- 35. (New) A method of reducing neuronal cell death in a mammal suffering from or susceptible to cerebral ischaemia, traumatic neuronal injury, paralysis, or spinal cord injury, comprising administering to the mammal an effective amount of a 3-substituted indolone that is a C-Raf inhibitor or a pharmaceutically acceptable salt-thereof sufficient to reduce neuronal cell death.